Majid Al-Futtaim gets exclusive naming rights

Khaled Al-Ajmi, country head of Majid Al-Futtaim — properties, accepted the award presented by Prince Faisal bin Bandar bin Abdulaziz.
Updated 21 November 2018

Majid Al-Futtaim gets exclusive naming rights

Majid Al-Futtaim, a shopping mall, communities, retail and leisure pioneer across the Middle East, Africa and Asia, has been awarded exclusive naming rights of the Riyadh Metro Station located close to its upcoming mall, City Centre Ishbiliyah. The station will be called City Centre Ishbiliyah Metro Station.

Khaled Al-Ajmi, the country head of Majid Al-Futtaim — properties, accepted the award, which was presented by Prince Faisal bin Bandar bin Abdulaziz, high commissioner for the development of Riyadh and chairman of the committee responsible for the Riyadh Public Transport Network, at an awards ceremony held at the Cultural Palace, Riyadh, on Nov. 14. 

“We are proud to have been awarded the naming rights to the City Centre Ishbiliyah Metro Station in partnership with the Riyadh Development Authority and Riyadh Metro and fully support their objective of creating world-class sustainable and innovative urban developments. City Centre Ishbiliyah is planned to be a LEED Gold-certified shopping mall for excellence in energy and design, which is a testament to the importance we place on sustainability in all the group’s projects,” Al-Ajmi said. 

“We would like to extend our group’s gratitude to Prince Faisal bin Bandar bin Abdulaziz for his vision and leadership in building world-class transportation infrastructure designed to improve the lives of Riyadh’s residents. This project further reflects the partnership and collaborative efforts of the UAE and the Kingdom of Saudi Arabia,” he added.


Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

Updated 27 May 2020

Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

  • Trials are being led locally as an essential means to verify the safety and effectiveness of a new drug
  • Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic

RIYADH: Clinical trials in Saudi Arabia could speed up the adoption of new drugs locally, a pharmaceutical executive has told Arab News.

“Clinical trials have two very big benefits for the Kingdom. Firstly, they provide data in the long run with respect to safety and efficacy, catered specifically to the Saudi population. Secondly, they impact local investment and build healthcare capabilities,” Managing Director of Eli Lilly Dimitri Livadas said..

Lividas further explained that the clinical trial phase of any new treatment is crucial as it represents the stage between the adoption or rejection of a drug. Working with the Ministry of Health and with a presence in the Kingdom for 42 years, the pharmaceutical company began research trials in the country in 2016, consisting of five pre-marketing activities and three monitoring studies for post-marketing.

Lividas added that the trials are being led locally as an essential means to verify the safety and effectiveness of a new drug before it is put to the market and introduced to patients. The majority of these are focused on diabetes, oncology, immunology, and osteoporosis.

“We genuinely believe that our future is here in Saudi Arabia. We continue to make great progress in having a commercial organization in the Kingdom that is fully staffed by Saudi nationals,” said Lividas.

As a biopharmaceutical company, Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic. It recently announced partnership with AbCellera to develop a treatment for the virus and aims to enter into clinical trials this year.

“I salute the Saudi authorities for their strong measures to contain the spread of COVID-19. I think it is an example to the world on how to do this. I would like to also express my gratitude toward all healthcare professionals who are currently on the frontlines, risking their own health to help others," Lividas said.